TSS
ESLA icon

Two Sigma Securities’s Estrella Immunopharma ESLA Stock Holding History

Two Sigma Securities’s Portfolio ESLA Stock Details ESLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,640
Closed -$12.8K – 1662
2024
Q4 		$12.8K Buy
+10,640
New +$10.7K ﹤0.01% 1400

Other funds holding ESLA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
ASM
ATW SPAC Management New York $79.2M AUM 10.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MCP
Maso Capital Partners Hong Kong $60.9M AUM 0.32% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Two Sigma Securities's ESLA Position: Q1 2025 in Review

Two Sigma Securities sold out of Estrella Immunopharma (ESLA) in Q1 2025, closing a stake of 10,640 shares — an estimated $12.8K sold.

Two Sigma Securities first reported a position in ESLA in Q4 2024 and held it in 1 quarter. The position peaked at $12.8K in Q4 2024. 11 funds tracked by Wall St. Rank hold ESLA as of Q1 2025.

  • Two Sigma Securities reported no remaining Estrella Immunopharma position as of Q1 2025 after selling out during the quarter.
  • Two Sigma Securities sold 10,640 Estrella Immunopharma shares in Q1 2025, an estimated $12.8K.
  • Two Sigma Securities first reported a position in Estrella Immunopharma in Q4 2024 and held it in 1 quarter.
  • Two Sigma Securities's Estrella Immunopharma position peaked at $12.8K in Q4 2024.
  • 11 funds tracked by Wall St. Rank held Estrella Immunopharma as of Q1 2025.

Based on Two Sigma Securities's 13F filing for Q1 2025, filed 15 May 2025.